DAFNA Capital Management LLC lowered its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 60.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 47,453 shares of the company's stock after selling 72,898 shares during the period. DAFNA Capital Management LLC's holdings in Centessa Pharmaceuticals were worth $795,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $5,083,000. Cutter Capital Management LP bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $2,464,000. BNP Paribas Financial Markets bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $162,000. Ameriprise Financial Inc. bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $320,000. Finally, Allostery Investments LP bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $4,766,000. Institutional investors own 82.01% of the company's stock.
Centessa Pharmaceuticals Stock Performance
Shares of NASDAQ:CNTA traded down $0.59 during trading on Tuesday, reaching $12.56. The stock had a trading volume of 201,104 shares, compared to its average volume of 624,152. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -8.21 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $13.79 and a two-hundred day simple moving average of $15.66.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. As a group, analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.
Insider Buying and Selling at Centessa Pharmaceuticals
In other news, insider David M. Chao sold 7,000 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $17.17, for a total value of $120,190.00. Following the transaction, the insider now owns 225,007 shares of the company's stock, valued at approximately $3,863,370.19. This trade represents a 3.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the sale, the chief executive officer now owns 331,017 shares in the company, valued at $5,273,100.81. This represents a 14.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 171,398 shares of company stock valued at $2,697,422. 11.59% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several research analysts have commented on the stock. Chardan Capital assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 target price for the company. Guggenheim reiterated a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Morgan Stanley restated an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a report on Thursday. They set an "outperform" rating and a $6.00 price target for the company. Finally, Piper Sandler began coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They set an "overweight" rating and a $38.00 price target for the company. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $27.00.
Check Out Our Latest Stock Report on CNTA
About Centessa Pharmaceuticals
(
Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Read More
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
